||5R01CA208758-03 Interpret this number
||Targeted Payment Cuts to Reduce Unproven Care
Reducing reimbursement levels within a fee-for-service environment is a promising approach for reducing
ineffective and unproven care when revoking coverage entirely or shifting financial risk to providers are
infeasible. Intensity-modulated radiation therapy (IMRT) was rapidly adopted into practice as a treatment for
breast and prostate cancer patients in the early to mid-2000s despite the absence of high quality evidence
demonstrating its superiority to conventional radiotherapy. Based on the rising volume of claims for IMRT and
a Wall St. Journal article calling attention to the perverse incentives inherent in physician self-referral for IMRT,
the Centers for Medicare & Medicaid Services (CMS) cut the payment rate for IMRT by 15% between 2012
and 2013. Using Medicare claims data, we propose to study the impact of the payment cut on the use of IMRT
and medical costs. We will study trends in the use of IMRT across three patient groups that differ in their ability
to benefit from IMRT: prostate cancer patients receiving initial treatment, prostate cancer patients receiving
radiotherapy following prostatectomy, and breast cancer patients receiving radiotherapy following breast
conserving surgery. We will use several strategies to accurately estimate the impact of the payment cut. The
magnitude of the cut differed across CMS payment areas. We will determine if declines in the use of IMRT
were larger in areas that experienced steeper cuts. Separately, we will compare trends in the use of IMRT in
three practice settings that differ in terms of the impact of the cut on practice income: self-referring physician
offices, non-self-referring physician offices, and hospital outpatient departments (which were unaffected by the
Medicare fee reductions and the overuse of intensity-modulated radiotherapy.
, Hockenberry J.
Health services research, 2021 Aug; 56(4), p. 626-634.
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
, Hall I.J.
, Filson C.
, Howard D.H.
Urologic oncology, 2021 Jul; 39(7), p. 432.e1-432.e10.
Intensity-Modulated Radiation Therapy in Breast Cancer Patients Following the Release of a Choosing Wisely Recommendation.
, Gogineni K.
, Howard D.H.
Journal of the National Cancer Institute, 2020-03-01; 112(3), p. 314-317.